Ira Shoulson - Alterity Therapeutics Director
| PRNAF Stock | USD 0.0002 0.00 0.00% |
Director
Dr. Ira Shoulson serves as a NonExecutive Director of the company. He is the Chairman of our Research and Development Advisory Board. He is the Louis C. Lasagna Professor of Experimental Therapeutics and Professor of Neurology, Pharmacology and Medicine at the University of Rochester School of Medicine in Rochester, New York. He received his MD degree and postdoctoral training in medicine and neurology at the University of Rochester and in experimental therapeutics at the National Institutes of Health since 2014.
| Tenure | 10 years |
| Phone | 61 3 9349 4906 |
| Web | https://alteritytherapeutics.com |
Alterity Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2585) % which means that it has lost $0.2585 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3897) %, meaning that it generated substantial loss on money invested by shareholders. Alterity Therapeutics' management efficiency ratios could be used to measure how well Alterity Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| John Suk | Covalon Technologies | N/A | |
| Jeffrey Mandel | Covalon Technologies | N/A | |
| Murray Miller | Covalon Technologies | N/A | |
| Myrna Francis | Covalon Technologies | N/A | |
| Ulrich Kosciessa | Ceapro Inc | N/A | |
| Ian Brindle | Covalon Technologies | N/A | |
| Ronald Smith | Covalon Technologies | 66 | |
| Donald Oborowsky | Ceapro Inc | N/A | |
| Martin Bernholtz | Covalon Technologies | N/A | |
| Elinor Caplan | Covalon Technologies | N/A | |
| Gale Pollock | Covalon Technologies | N/A | |
| Joseph Cordiano | Covalon Technologies | N/A | |
| William Li | Ceapro Inc | 49 | |
| John Zupancic | Ceapro Inc | N/A | |
| Glenn Rourke | Ceapro Inc | N/A | |
| John Hands | Covalon Technologies | N/A | |
Management Performance
| Return On Equity | -0.39 | |||
| Return On Asset | -0.26 |
Alterity Therapeutics Leadership Team
Elected by the shareholders, the Alterity Therapeutics' board of directors comprises two types of representatives: Alterity Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alterity. The board's role is to monitor Alterity Therapeutics' management team and ensure that shareholders' interests are well served. Alterity Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alterity Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lawrence Gozlan, Non-Executive Independent Director | ||
| BBus CA, Company Sec | ||
| Peter Marks, Non-Executive Independent Director | ||
| BSc BSc, CoFounder Chairman | ||
| Steven Targum, Chief Advisor | ||
| David Stamler, Chief Medical Officer and Senior Vice President Clinical Development | ||
| George Mihaly, Non-Executive Independent Director | ||
| Geoffrey Kempler, Executive Chairman of the Board, CEO | ||
| Tristan Edwards, Director | ||
| Rudolph Tanzi, Chief Board | ||
| Robert Cherny, Head Research | ||
| Ira Shoulson, Director | ||
| David Sinclair, Director | ||
| Dianne Angus, COO | ||
| Phillip Hains, Company Secretary | ||
| Kathryn Andrews, Chief Officer | ||
| Brian Meltzer, Non-Executive Independent Director | ||
| David MD, Chief Officer |
Alterity Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Alterity Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.39 | |||
| Return On Asset | -0.26 | |||
| Profit Margin | (2.51) % | |||
| Operating Margin | (3.03) % | |||
| Current Valuation | (7.2 M) | |||
| Shares Outstanding | 2.41 B | |||
| Shares Owned By Insiders | 15.14 % | |||
| Shares Owned By Institutions | 0.33 % | |||
| Price To Earning | 0.88 X | |||
| Price To Book | 0.67 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Alterity Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Alterity Therapeutics' short interest history, or implied volatility extrapolated from Alterity Therapeutics options trading.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Alterity Therapeutics using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Alterity Therapeutics Limited. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in Alterity Pink Sheet please use our How to Invest in Alterity Therapeutics guide.Note that the Alterity Therapeutics information on this page should be used as a complementary analysis to other Alterity Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Complementary Tools for Alterity Pink Sheet analysis
When running Alterity Therapeutics' price analysis, check to measure Alterity Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alterity Therapeutics is operating at the current time. Most of Alterity Therapeutics' value examination focuses on studying past and present price action to predict the probability of Alterity Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alterity Therapeutics' price. Additionally, you may evaluate how the addition of Alterity Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |